title: Lanthanum carbonate treatment of patients with hyperphosphatemia undergoing CAPD.
authors.forename: H
authors.initials: H
authors.lastname: Kawanishi
authors.forename: M
authors.initials: M
authors.lastname: Ishida
authors.forename: M
authors.initials: M
authors.lastname: Ishizaki
authors.forename: Y
authors.initials: Y
authors.lastname: Takuma
authors.forename: H
authors.initials: H
authors.lastname: Tamura
authors.forename: S
authors.initials: S
authors.lastname: Kobayashi
authors.forename: T
authors.initials: T
authors.lastname: Tamura
authors.forename: H
authors.initials: H
authors.lastname: Ohashi
authors.forename: M
authors.initials: M
authors.lastname: Hiramatsu
authors.forename: J
authors.initials: J
authors.lastname: Minakuchi
authors.forename: H
authors.initials: H
authors.lastname: Hirakata
authors.forename: T
authors.initials: T
authors.lastname: Shigematsu
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D007811:Lanthanum / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D010531:Peritoneal Dialysis, Continuous Ambulatory
chemical_list: C119467:lanthanum carbonate; D007811:Lanthanum